secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxart, Inc. (VXRT)
CIK:        0000072444
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001437749-24-025539
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxart Q2 net loss narrows to $16.5M; BARDA award up to $453M for COVID Phase 2b
--------------------------------------------------------------------------------

- Net loss per share $0.09 vs $0.16 YoY; revenue $6.4M (from $1.4M) on BARDA contract.
- Cash and investments $62.6M at June 30; received ~$64.7M BARDA payment post-quarter.
- BARDA Project NextGen award up to $453M to support 10,000-subject Phase 2b COVID trial vs mRNA comparator.
- Enrollment for Phase 2b expected in H2 2024 pending FDA alignment; cash runway into 2026.
- Norovirus vaccine: in discussions with FDA on correlates of protection; evaluating Phase 2b/challenge study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/72444/000143774924025539/0001437749-24-025539-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/72444/000143774924025539/vxrt20240529_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-025539

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer